Latest Investor Conference Call
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedence spectroscopy (BIS) technology to generate powerful data to maximise patient health.
ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.
ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.
To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:
Locked Bag A14
NSW 1235, Australia
For every 1 New Share issued under the Company’s Accelerated Entitlement Offer, Eligible Shareholders were issued 1 free New Option, exercisable at a price of $0.0375 (3.75 cents) each.
The New Options are exercisable in whole or part on 30 June 2020, 30 September 2020, 31 December 2020, and 31 March 2021 (the date of their expiry) at a price of $0.0375 (3.75 cents) each, but not thereafter. New Options not exercised by 5pm (Sydney time) on 31 March 2021 will lapse.
Each New Option entitles the holder to subscribe for one Share. Any Shares issues as a result of exercising a New Option will be issued on the same terms and rank in all respects with existing Shares.
Each eligible Securityholder of New Options was provided a holding statement by the Share Registry that set out the number of New Options allotted to them. The notice also advised holders of their Security Holder Reference Number, the exercise price of the Options, and the date of issue of the New Options and the New Option Exercise Dates.
When exercising New Options, a New Option holder must give the Company or the Share Registry a Notice of Exercise of Options form, together with payment of the exercise monies payable to the Company in connection with the Options being exercised on or prior to the relevant New Option Exercise Date of Wednesday, 31 March 2021.
To assist Option holders with the final expiry, a personalised Notice of Exercise of Options form, with BPay facility, has been sent to all Option holders that have unexercised options. If you have not received this form by 26 February 2021 or have any questions regarding your eligibility to the Options, please contact Link Market Services or the Company on the phone numbers provided.
Option holders who wish to exercise all or part of their Options must give the Company or the Share Registry a Notice of Exercise of Options form, together with payment of the exercise monies payable to the Company in connection with the Options being exercised [being $0.0375 (3.75 cents) per Option] prior to 5.00pm (Sydney time) on Wednesday, 31 March 2021.
The Company shall within five Business Days after the relevant New Option Exercise Date, subject to receipt of a Notice of Exercise of Option Form and cleared funds, issue Shares in respect of the New Options exercised and dispatch a holding statement to the holder. An application for official quotation of the Shares allotted and issued as a result of the exercise of the New Options will be made within ten Business Days after the date of issue of the Shares.
Refer to Section 9.2 of the Prospectus for the full terms and conditions of the New Options.
Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:
ImpediMed maintains an active communications program with investors and the market. If you are interested in a presentation, please contact:
Investor Relations Contact:
Mike Bassett, Senior Vice President, Corporate and Strategic Development, ImpediMed
+61 4 0743 1432
Kyahn Williamson, WE Buchan
+61 3 9866 4722